What is Intrapace?
Intrapace is at the forefront of developing novel therapeutic solutions for complex gastrointestinal disorders, including Crohn's disease and ulcerative colitis. The company's innovation pipeline encompasses advancements in Inflammatory Bowel Disease (IBD) diagnosis, sensing technologies for inflammation and ischemia, localized drug delivery systems, and surgical marking applications. This focus positions Intrapace as a key player in the medical technology sector, aiming to significantly improve patient outcomes through targeted and innovative treatments.
How much funding has Intrapace raised?
Intrapace has raised a total of $129.3M across 5 funding rounds:
Unspecified
$116.9M
Unspecified
$6.2M
Multiple Rounds
$6.2M
Unspecified (2010): $116.9M, investors not publicly disclosed
Unspecified (2012): $6.2M, investors not publicly disclosed
Debt (2013): $624K, investors not publicly disclosed
Unspecified (2013): $2.2M, investors not publicly disclosed
Unspecified (2013): $3.3M, investors not publicly disclosed
What's next for Intrapace?
With the recent infusion of major strategic capital, Intrapace is poised for an accelerated growth phase. The company is expected to leverage this investment to further refine its diagnostic tools and localized drug delivery platforms, potentially expanding its clinical trial pipeline and preparing for broader market adoption. This funding signifies strong investor confidence in Intrapace's technological capabilities and its potential to disrupt the treatment landscape for gastrointestinal conditions.
See full Intrapace company page
